Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

J Diabetes Complications. 2017 Jul;31(7):1164-1168. doi: 10.1016/j.jdiacomp.2017.04.003. Epub 2017 Apr 11.

Abstract

Aims: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.

Methods: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.

Results: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).

Conclusions: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.

Keywords: Estimated glomerular filtration rate; Kidney function; Liraglutide; Obesity; Serum creatinine.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / therapeutic use
  • Biomarkers / blood
  • Body Mass Index
  • Combined Modality Therapy / adverse effects
  • Creatinine / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetic Nephropathies / chemically induced
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / prevention & control*
  • Double-Blind Method
  • Female
  • Glomerular Filtration Rate / drug effects
  • Glycated Hemoglobin A / analysis
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Kidney / drug effects
  • Kidney / physiopathology*
  • Liraglutide / adverse effects
  • Liraglutide / therapeutic use
  • Male
  • Middle Aged
  • Obesity / complications
  • Obesity / drug therapy
  • Obesity / physiopathology
  • Obesity / therapy*
  • Prediabetic State / blood
  • Prediabetic State / complications*
  • Prediabetic State / drug therapy
  • Renal Insufficiency / chemically induced
  • Renal Insufficiency / complications
  • Renal Insufficiency / etiology
  • Renal Insufficiency / prevention & control*
  • Weight Loss / drug effects

Substances

  • Anti-Obesity Agents
  • Biomarkers
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human
  • Liraglutide
  • Creatinine

Associated data

  • ClinicalTrials.gov/NCT01272232